
Please try another search
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Name | Age | Since | Title |
---|---|---|---|
Simon Nebel | 55 | 2017 | Independent Chairman of Supervisory Board |
Karl Mahler | - | 2024 | Member of Supervisory Board. |
Talin Barisani | - | - | Member of Scientific Advisory Board |
Julian Crane | - | - | Member of Scientific Advisory Board |
Ron Eccles | - | - | Member of Scientific Advisory Board |
Elisabeth Lackner | 52 | 2022 | Independent Member of Supervisory Board |
Balamurali Ambati | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review